Trial Profile
A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 Administered Weekly in 4-weeks in Patients With Type 2 Diabetes Mellitus on Stable Metformin and Exenatide therapy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs RO 5095932 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Roche
- 19 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 May 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.